Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Two-period Crossover Study Evaluating the Effects of Tasimelteon vs. Placebo on Sleep Disturbances of Individuals With Smith-Magenis Syndrome (SMS)

NCT02231008 is registered in ClinicalTrials.gov with Vanda Pharmaceuticals as lead sponsor.

NCT NCT02231008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02231008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Two-period Crossover Study Evaluating the Effects of Tasimelteon vs. Placebo on Sleep Disturbances of Individuals With Smith-Magenis Syndrome (SMS)
Lead sponsor
Vanda Pharmaceuticals
Phase
Phase 2/3
Overall status
Completed
Start date
September 30, 2015
Completion date
January 31, 2022
Enrollment
49 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

circadian, smith-magenis syndrome